Engineered immune cells take on deadly brain tumors
NCT ID NCT06355908
First seen Jan 22, 2026 · Last updated May 08, 2026 · Updated 16 times
Summary
This early-stage trial tests a new treatment for people with a severe type of brain cancer (grade 4 glioma) that has come back or not responded to standard therapies. The treatment uses the patient's own immune cells, modified in a lab to target a protein called IL-13Rα2 found on the tumor cells. The main goal is to check the safety of this approach and see if it can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tiantan Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.